期刊文献+

二甲双胍与阿卡波糖对社区糖尿病患者的治疗效果对比 被引量:3

下载PDF
导出
摘要 目的:比较分析二甲双胍以及阿卡波糖对社区糖尿病患者的治疗效果。方法:选取2013年10月至2018年10月在本院全科就诊的357例社区糖尿病患者,随机分为二甲双胍组(n=178例)和阿卡波糖组(n=179例)。二甲双胍组口服二甲双胍,每次给药500mg,每天1次;阿卡波糖组口服阿卡波糖,起始给药剂量为每次50mg,每天3次,逐渐将剂量升高至每次100mg,每天3次。结果:阿卡波糖组的治疗有效率为91.06%(163/179),明显高于二甲双胍组的74.16%(132/178)(P<0.05);两组治疗后的空腹血糖、总胆固醇、餐后2h血糖水平均明显降低(P<0.05),且二甲双胍组的总胆固醇水平明显低于阿卡波糖组(P<0.05),阿卡波糖组的血糖水平明显低于二甲双胍组(P<0.05)。结论:二甲双胍以及阿卡波糖均为治疗社区糖尿病患者的有效药物,其中二甲双胍具有较好的降脂效果,阿卡波糖具有较好的血糖控制效果。
作者 杨晶晶
出处 《中外女性健康研究》 2019年第5期129-129,160,共2页 Women's Health Research
  • 相关文献

参考文献6

二级参考文献85

  • 1Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monothe~apy or added to metformin,is primarily as a result of a reduction in fat tissue [J]. Diabetes Obes Metab, 2009,11 (12) : 1163- 1172.
  • 2Tremblay AJ,Lamarche B,Lemelin N,et al. Effect of sitagliptin therapy on postprandial lipoprotein level in patient with type 2 diabetes [J]. Diabetes Obes Metab,2011,13 (4) : 366-373.
  • 3Ross SA,Rafeiro E, Meinicke T,et al. Efficacy and safety of Linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin : a randomized, double-blind, placebo-controlled trial [J]. Curt Med Res Opin,2012,28(9): 1465-1474.
  • 4Blonde L,Dagogo-Jaek S,Banerji MA,et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin:resuhs of the Galiant Trial : a primary care,type 2 diabetes study [J]. Diabetes Obes Metab, 2009,11 (10) : 978-986.
  • 5Matthews DR, Dejager S,Ahren B, et al. Vildagliptin add on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride,with no weight gain:results from a 2 year study [J]. Diabetes Obes Metab,2010,12(9) :780-789.
  • 6Mohan V, Yang W, Son HY , et al. Efficacy and safety of Sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea [J]. Diabetes Res Clin Pract, 2009,83 ( 1 ) : 106-116.
  • 7Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase -4 inhibitor, Sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin [J]. Diabetes Obes Metab,2007,9(5):733-745.
  • 8Aschner P,Katzeff HL,Guo H,et al. Efficacy and safety of monotherapy of Sitagliptin compared with mefformin in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2010,12(3) : 252-261.
  • 9Garber A,Henry R,Ratner R,et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3Mono) :a randomized,52-week, phsae III ,double-blinded,parallel treatment trial [J]. Lancet, 2009,373 (9662) : 473-481.
  • 10DeFronzo RA, Hissa MN, Garber AJ,et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone [J]. Diabetes Care,2009, 32(9) : 1649-1655.

共引文献312

同被引文献22

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部